Evidence map›Paper›PMID 33837058›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2021

Effect of Teriflunomide on Cells From Patients With Human T-cell Lymphotropic Virus Type 1-Associated Neurologic Disease.

Yoshimi Enose-Akahata, Nyater Ngouth, Joan Ohayon, Matt Mandel, Jeffrey Chavin, Timothy J Turner, Steven Jacobson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP.Annals of clinical and translational neurology · 2021
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Therapeutic advances in neuroinfectious diseases.Therapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yoshimi Enose-AkahataFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.ORCID 0000-0002-7102-9703
Nyater NgouthFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.
Joan OhayonFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.
Matt MandelFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.
Jeffrey ChavinFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.
Timothy J TurnerFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA.
Steven JacobsonFrom the Viral Immunology Section (Y.E.-A., N.N., S.J.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Joan Ohayon, Neuroimmunology Clinic (J.O.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and Sanofi (M.M., J.C., T.J.T.), Cambridge, MA. jacobsons@ninds.nih.gov.
National Institutes of Health · US

Funding

Involvement Of Human Viruses Associated With Chronic Neurologic DiseaseZIANS002817 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 2009 to 2025
$26.5M
NINDS NIH HHS
6 · The paper itself

Abstract

objectiveTo test the hypothesis that teriflunomide can reduce ex vivo spontaneous proliferation of peripheral blood mononuclear cells (PBMCs) from patients with human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

methodsPBMCs from patients with HAM/TSP were cultured in the presence and absence of teriflunomide and assessed for cell viability, lymphocyte proliferation, activation markers, HTLV-1

resultsIn culture, teriflunomide did not affect cell viability. A concentration-dependent reduction in spontaneous proliferation of PBMCs was observed with 25 μM (38.3% inhibition), 50 μM (65.8% inhibition), and 100 μM (90.7% inhibition) teriflunomide. The inhibitory effects of teriflunomide were detected in both CD8

conclusionsThese results suggest that teriflunomide inhibits abnormal T-cell proliferation associated with HTLV-1 infection and may have potential as a therapeutic option in patients with HAM/TSP.

Indexed as

AdultAgedCell ProliferationCell SurvivalCrotonatesFemaleGene Products, taxHTLV-I InfectionsHumansHuman T-lymphotropic virus 1HydroxybutyratesLeukocytes, MononuclearMaleMiddle AgedNitrilesParaparesis, Tropical SpasticCrotonatesGene Products, taxHydroxybutyratesNitrilesRNA, MessengerteriflunomideToluidines

Identifiers

PMID33837058
PMCPMC8054963
OpenAlexW3147506416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.